Analysts forecast that Synlogic Inc (NASDAQ:SYBX) will post sales of $980,000.00 for the current quarter, Zacks reports. Five analysts have provided estimates for Synlogic’s earnings, with the lowest sales estimate coming in at $300,000.00 and the highest estimate coming in at $3.13 million. Synlogic reported sales of $250,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 292%. The company is expected to issue its next quarterly earnings results on Wednesday, August 14th.
On average, analysts expect that Synlogic will report full-year sales of $2.04 million for the current year, with estimates ranging from $300,000.00 to $4.71 million. For the next fiscal year, analysts forecast that the business will post sales of $1.68 million, with estimates ranging from $1.30 million to $2.40 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Synlogic.
Synlogic (NASDAQ:SYBX) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.51) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.54) by $0.03. The business had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.42 million. Synlogic had a negative return on equity of 38.93% and a negative net margin of 2,005.43%.
Shares of NASDAQ:SYBX traded down $0.05 on Friday, hitting $7.72. 229,923 shares of the company’s stock were exchanged, compared to its average volume of 92,676. The stock has a market cap of $197.28 million, a P/E ratio of -3.80 and a beta of 2.31. Synlogic has a 1-year low of $5.75 and a 1-year high of $14.59. The company has a debt-to-equity ratio of 0.20, a quick ratio of 11.53 and a current ratio of 11.53.
Institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc purchased a new position in shares of Synlogic in the 3rd quarter worth $33,000. Bank of Montreal Can raised its position in shares of Synlogic by 5,743.1% in the 1st quarter. Bank of Montreal Can now owns 12,738 shares of the biotechnology company’s stock worth $97,000 after buying an additional 12,520 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Synlogic in the 1st quarter worth $114,000. Rhumbline Advisers raised its position in shares of Synlogic by 45.7% in the 4th quarter. Rhumbline Advisers now owns 21,753 shares of the biotechnology company’s stock worth $152,000 after buying an additional 6,820 shares during the period. Finally, State of Wisconsin Investment Board raised its position in shares of Synlogic by 29.8% in the 1st quarter. State of Wisconsin Investment Board now owns 20,900 shares of the biotechnology company’s stock worth $159,000 after buying an additional 4,800 shares during the period. 81.89% of the stock is currently owned by institutional investors and hedge funds.
Synlogic Company Profile
Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.
Featured Story: Real Estate Investment Trust (REIT) ETF
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.